androgenetic alopecia:
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
296 |
4. Check minimum number of eventsNone |
296 |
5. Include endpointsNone |
296 |
6. Filter based on genotype QC (FinnGen only) |
296 |
Control definitions (FinnGen only)
- Control exclude
- L12_DISORDSKINAPPENDIX
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L60-L75
- Name in latin
- Alopecia androgenica
Similar endpoints
↥List of similar endpoints to
Androgenic alopecia
based on the number of shared cases.
Similar with more cases:
- Disorders of skin appendages
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1684 | 1684 | - |
| Only index persons | 1625 | 1625 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.05 | - |
| Only index persons | 0.06 | 0.06 | - |
| Median age at first event (years) | |||
| Whole population | - | 43.96 | - |
| Only index persons | - | 43.20 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 296 | 296 | - |
| Unadjusted period prevalence (%) | 0.10 | 0.10 | - |
| Median age at first event (years) | 50.59 | 50.59 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 260
- Matched controls
- 2599
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L64.9
ICD-10 Finland
Androgenic alopecia, unspecified
4439.5
197.4
165
*
L64.8
ICD-10 Finland
Other androgenic alopecia
+∞
103.2
92
*
C03DA01
ATC
spironolactone; oral
12.2
40.3
78
88
L65.9
ICD-10 Finland
Nonscarring hair loss, unspecified
+∞
25.4
24
*
L63.9
ICD-10 Finland
Alopecia areata, unspecified
143.8
25.1
26
*
L63.8
ICD-10 Finland
Other alopecia areata
204.1
18.8
19
*
D07AC01
ATC
betamethasone; topical
3.3
17.9
134
640
D07AC13
ATC
mometasone; topical
3.2
16.6
116
520
L63.0
ICD-10 Finland
Alopecia (capitis) totalis
+∞
12.6
12
*
L64.0
ICD-10 Finland
Drug-induced androgenic alopecia
+∞
12.6
12
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.8
12.0
55
173
D07AB02
ATC
hydrocortisone butyrate; topical
2.5
9.8
96
490
D07AD01
ATC
clobetasol; topical
2.9
9.3
63
261
S23
ICPC
Hair loss/baldness
19.5
9.0
13
7
L68.0
ICD-10 Finland
Hirsutism
46.4
7.8
9
*
G04CB01
ATC
finasteride; oral (testosterone-5-alpha reductase inhibitors)
46.4
7.8
9
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.5
7.5
35
111
L65.8
ICD-10 Finland
Other specified nonscarring hair loss
82.3
7.5
8
*
L64
ICD-10 Finland
Androgenic alopecia
82.3
7.5
8
*
H03AA01
ATC
levothyroxine sodium; systemic
2.1
6.9
91
523
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.0
6.8
116
741
XQ802
NOMESCO Finland
Epicutan test
4.5
6.6
22
52
B07.9
ICD-10 Finland
Verruca simplex
5.2
6.5
19
39
E0000UV
ATC
NA
2.0
6.5
122
806
G03HA01
ATC
cyproterone; systemic
71.5
6.5
7
*
L21.0
ICD-10 Finland
Seborrhoea capitis
18.6
6.3
9
5
SPAT1260
SPAT
Consultation of another employee
2.4
6.1
57
277
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
6.1
124
836
K03.00
ICD-10 Finland
Approximal wear
4.3
6.1
21
52
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
105
4.25
14.13
1.4
1.3
0.3
0.3
u/ml
—
5
7
119
681
2.25
10.04
1.5
1.3
1.0
1.9
u/ml
0.64
32
185
265
2159
3.17
9.16
6.6
4.3
14.9
14.5
pmol/l
1.30
247
1986
181
1264
2.11
8.78
3.5
2.7
71.8
78.4
ug/l
0.33
175
1168
242
1905
2.48
8.59
7.3
6.6
73.8
74.4
u/l
0.11
224
1770
94
540
2.09
7.47
2.4
2.8
715.4
850.2
ng/l
0.19
77
453
116
730
1.97
7.09
3.3
2.2
57.0
55.5
u/l
0.19
107
669
143
966
1.93
7.08
2.2
1.9
95.8
98.4
pmol/l
0.29
74
457
143
973
1.91
6.87
5.4
3.8
36.7
36.2
g/l
0.59
135
905
161
1139
1.91
6.86
2.5
2.2
81.0
78.8
nmol/l
0.44
153
1024
164
1174
1.89
6.67
6.8
5.5
1.2
1.2
mmol/l
2.06
143
984
172
1261
1.87
6.38
5.3
5.2
9.0
9.6
umol/l
0.70
164
1180
235
1938
2.03
5.76
5.2
4.0
11.7
11.0
mm/h
0.37
223
1781
189
1461
1.81
5.57
7.4
8.4
4.0
3.9
e9/l
0.10
167
1282
117
786
1.81
5.55
3.0
2.8
—
—
—
0
0
93
585
1.86
5.44
1.7
1.7
1.0
0.8
mg/l
0.29
69
441
39
177
2.39
5.42
1.4
1.3
17.6
25.5
iu/l
1.23
32
155
24
85
2.98
5.39
1.3
1.2
6.8
8.1
u/ml
—
5
17
278
2475
3.03
5.36
8.1
5.1
1.8
2.3
mu/l
0.54
266
2296
50
254
2.17
5.33
2.3
2.0
4.3
5.1
umol/l
0.59
40
215
120
820
1.78
5.33
3.5
3.1
12.2
25.1
ng/l
1.04
67
489
45
221
2.22
5.21
1.4
1.3
114.0
154.3
iu/ml
0.37
20
94
106
706
1.78
5.09
2.3
2.0
158.8
137.0
u/l
0.30
101
665
54
289
2.06
5.03
7.8
5.4
—
—
—
0
0
210
1702
1.80
5.00
5.8
4.3
—
1808.7
—
0
24
91
585
1.80
4.90
2.5
2.0
3.0
3.0
mg/l
0.03
81
490
58
327
1.96
4.67
2.4
2.1
13.3
13.8
umol/l
0.27
52
300
174
1353
1.69
4.64
6.2
3.9
6.5
6.4
mmol/l
0.10
168
1231
31
136
2.43
4.64
1.6
1.4
—
—
—
0
0
165
1276
1.66
4.41
5.0
3.5
0.0
0.0
estimate
0.00
26
255
142
1057
1.66
4.40
6.1
4.8
1.2
1.2
mmol/l
2.17
129
954
44
230
2.07
4.35
2.2
2.9
20.0
37.5
u/ml
0.93
39
221
75
477
1.77
4.11
1.8
1.6
453.9
30904983.3
pmol/l
0.78
64
398
164
1282
1.63
4.07
6.9
4.7
0.0
0.0
estimate
0.50
28
258
82
537
1.73
4.05
1.4
1.4
20.8
21.9
nmol/l
0.36
73
455
260
2306
2.05
4.04
6.9
5.0
39.5
38.5
mmol/mol
1.15
243
2156
119
863
1.63
3.98
2.9
3.2
2.4
2.4
mmol/l
0.50
103
763
71
450
1.76
3.92
2.6
2.6
2.4
2.4
mmol/l
1.12
60
399
281
2579
2.77
3.88
17.3
12.3
3.9
3.9
mmol/l
0.92
274
2499
79
518
1.72
3.87
1.3
1.3
41.5
37.4
iu/ml
0.05
18
168
16
55
3.02
3.80
1.8
1.5
32.3
23.2
u/l
0.51
16
44
164
1296
1.60
3.79
5.2
3.5
0.0
0.0
estimate
0.50
28
253
280
2574
2.62
3.69
17.2
12.2
139.3
139.8
mmol/l
2.56
274
2500
10
26
3.95
3.55
1.4
1.3
306.9
425.6
pmol/l
—
10
19
62
392
1.74
3.43
3.3
3.2
213.3
219.4
ng/l
0.01
41
271
265
2401
1.99
3.34
11.9
10.5
85.4
85.1
ml/min/173m2
0.08
220
1919
7
12
5.94
3.04
1.0
1.2
—
—
—
0
0
127
983
1.51
3.00
5.7
3.5
—
—
—
0
0
270
2483
1.99
2.93
5.4
4.2
5.9
5.7
mmol/l
0.79
256
2295
38
219
1.84
2.86
1.7
1.8
—
—
—
0
0
277
2576
2.17
2.82
15.2
11.2
19.0
19.9
mg/l
0.23
224
1945
16
66
2.51
2.76
1.3
1.3
—
—
—
0
0
5
6
8.45
2.76
1.2
4.5
148.8
109.3
%
—
5
6
85
618
1.53
2.64
2.8
2.7
0.2
0.5
e6/l
1.50
73
450
23
114
2.10
2.64
14.5
6.8
1.4
1.3
%
0.47
23
114
23
114
2.10
2.64
14.6
6.8
0.8
0.7
%
1.51
23
114
198
1704
1.49
2.63
3.7
2.7
37.0
36.9
u/l
0.01
188
1597
49
320
1.64
2.39
1.7
1.9
—
—
—
0
0
36
218
1.74
2.32
1.8
1.9
—
—
—
0
0
44
282
1.66
2.31
2.5
2.2
22.6
22.8
%
0.04
36
238
11
41
2.75
2.30
1.4
1.2
—
—
—
0
0
15
66
2.34
2.28
1.1
1.2
—
—
—
0
0
6
13
4.69
2.28
1.7
1.2
2.0
1.9
mmol/l
—
6
13
7
18
3.96
2.26
1.4
1.8
—
—
—
0
0
10
36
2.84
2.22
1.3
1.4
—
—
—
0
0
5
9
5.63
2.22
1.0
4.1
175.6
205.0
u/l
—
5
9
35
214
1.72
2.19
12.9
6.1
5.0
5.2
kpa
1.26
35
208
35
214
1.72
2.19
12.9
6.1
12.9
12.9
kpa
0.01
35
208
146
1213
1.40
2.18
5.3
3.9
—
—
—
0
0
53
362
1.57
2.16
2.1
2.5
0.9
1.1
e6/l
0.30
38
192
12
49
2.51
2.13
1.1
1.2
0.4
2.2
u/ml
—
5
17
35
216
1.70
2.12
12.9
6.1
0.9
1.4
mmol/l
0.27
30
173
19
96
2.05
2.10
2.4
2.2
—
—
—
0
0
71
523
1.47
2.04
1.3
1.3
3.6
11.2
u/ml
1.81
39
207
8
26
3.13
2.03
1.5
1.6
—
—
—
0
0
9
32
2.87
2.01
1.2
1.3
—
—
—
0
0
27
157
1.79
2.01
1.1
1.0
—
—
—
0
0
36
228
1.66
1.99
27.8
15.8
1.2
1.2
inr
—
8
38
14
66
2.18
1.85
2.4
1.7
—
206.7
—
0
6
7
23
3.09
1.81
1.4
1.7
—
—
—
0
0
11
47
2.39
1.80
3.7
2.7
4.0
4.5
e9/l
0.32
11
47
27
164
1.71
1.75
2.7
2.8
2.5
2.4
mmol/l
0.05
18
137
25
149
1.74
1.73
1.6
1.4
—
—
—
0
0
11
48
2.34
1.72
4.1
3.0
56.7
57.9
%
0.14
11
48
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
13
3.89
1.72
1.4
2.6
115.6
116.0
%
—
5
13
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
14
3.61
1.62
1.0
1.1
—
—
—
0
0
76
592
1.38
1.59
1.7
1.6
—
—
—
0
0
100
815
1.34
1.57
3.2
2.9
60.4
27.0
u/l
0.60
95
776
256
2400
1.49
1.57
4.3
3.6
1.4
1.2
mmol/l
3.47
240
2218
86
690
1.35
1.49
6.1
3.8
0.0
0.0
estimate
0.50
28
258
9
38
2.41
1.47
1.3
1.6
—
—
—
0
0
269
2558
1.57
1.42
5.6
4.6
2.8
2.9
mmol/l
0.73
253
2374
31
208
1.55
1.39
2.3
2.2
78.7
76.4
ml/min/173m2
0.12
12
73
9
41
2.23
1.38
1.3
1.5
—
—
—
0
0
75
597
1.34
1.36
2.1
2.0
—
—
—
0
0
5
17
2.97
1.36
1.2
1.2
—
—
—
0
0
13
68
1.95
1.35
1.2
1.1
—
—
—
0
0
266
2528
1.52
1.35
4.9
4.1
4.8
4.9
mmol/l
0.51
252
2357
12
61
2.01
1.34
2.2
3.5
3.7
3.8
mmol/l
0.75
12
55
252
2372
1.42
1.34
16.9
12.3
39.4
39.5
%
0.07
182
1801
29
194
1.55
1.33
1.7
1.6
—
—
—
0
0
8
34
2.39
1.30
1.8
2.3
13.1
13.2
%
—
8
34
10
48
2.12
1.29
1.4
2.4
—
—
—
0
0
5
19
2.66
1.22
1.0
1.2
—
—
—
0
0
86
711
1.30
1.19
1.6
1.4
—
—
—
0
0
263
2507
1.44
1.17
4.9
4.1
1.5
1.6
mmol/l
1.43
250
2334
17
105
1.66
1.08
2.5
1.7
—
—
—
0
0
52
406
1.34
1.08
1.6
1.6
1241.3
1198.0
nmol/l
0.12
40
300
11
60
1.87
1.04
2.3
1.6
—
—
—
0
0
5
22
2.29
1.04
1.0
1.3
—
—
—
0
0
85
715
1.26
1.02
1.7
1.6
1.4
1.3
mmol/l
0.68
79
617
14
84
1.70
0.99
4.1
3.1
46.7
45.0
%
0.07
14
84
17
108
1.61
0.99
1.6
2.5
0.0
0.1
e6/l
1.41
17
103
195
1802
1.24
0.98
3.5
3.5
—
—
—
0
0
6
28
2.17
0.92
2.3
1.3
—
—
—
0
0
20
139
1.47
0.81
1.5
1.8
3.3
2.2
mg/l
0.36
11
94
14
90
1.58
0.79
1.6
1.1
—
—
—
0
0
14
90
1.58
0.79
1.6
1.1
—
—
—
0
0
12
75
1.63
0.76
1.6
1.3
—
—
—
0
0
33
255
1.33
0.76
2.4
1.7
—
—
—
0
0
5
24
2.10
0.75
1.2
1.1
—
—
—
0
0
9
57
1.60
0.72
3.4
1.2
4.3
3.7
mmol/l
—
9
51
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
7
42
1.68
0.69
3.7
5.4
364.7
395.2
umol/l
—
7
37
5
27
1.87
0.68
1.0
1.1
—
—
—
0
0
41
335
1.26
0.64
2.0
2.6
2.5
4.0
e6/l
0.91
27
166
5
29
1.74
0.64
1.0
1.7
—
—
—
0
0
9
137
0.65
0.62
1.8
1.5
—
—
—
0
0
20
148
1.38
0.61
2.8
2.2
6271.9
3836.7
u/l
—
9
65
6
35
1.73
0.58
1.2
1.1
—
—
nmol/l
—
0
0
22
169
1.33
0.55
1.4
1.4
—
—
—
0
0
16
215
0.73
0.54
1.8
1.5
—
—
—
0
0
16
117
1.39
0.53
1.4
1.7
—
—
—
0
0
9
63
1.44
0.53
3.6
1.3
580.8
358.7
mg/l
—
9
58
13
92
1.43
0.51
3.2
2.7
26.7
25.2
mmol/l
0.64
13
92
12
85
1.43
0.47
3.4
1.9
2.8
6.6
iu/l
—
6
28
11
77
1.45
0.46
1.3
1.2
—
—
—
0
0
36
303
1.21
0.46
4.0
3.9
32.5
33.4
%
0.29
25
201
15
113
1.34
0.43
1.6
1.4
111.4
270.1
miu/ml
—
8
60
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
1.4
—
0
8
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
9
70
1.29
0.37
1.1
2.5
0.0
0.7
g/l
—
9
65
21
171
1.25
0.37
16.0
5.3
1.1
1.2
mmol/l
0.07
21
165
9
126
0.71
0.35
1.8
1.4
—
—
—
0
0
9
126
0.71
0.35
1.8
1.4
—
—
—
0
0
9
126
0.71
0.35
1.8
1.4
—
—
—
0
0
9
126
0.71
0.35
1.8
1.4
—
—
—
0
0
6
43
1.40
0.35
2.0
2.1
—
—
—
0
0
34
294
1.18
0.34
1.6
1.5
1.4
1.3
%
0.59
29
257
61
554
1.13
0.32
1.7
2.5
296.1
7134.1
umol/l
3.00
55
486
7
52
1.35
0.31
1.0
1.2
—
—
—
0
0
40
356
1.14
0.29
2.4
2.0
—
—
—
0
0
11
86
1.29
0.26
1.6
2.0
—
—
—
0
0
28
245
1.16
0.26
2.8
3.9
3.1
6.7
ug/l
1.11
17
195
31
275
1.14
0.24
2.2
1.6
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
18.0
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
97.9
—
0
10
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
6
49
1.23
0.20
1.0
5.3
13.8
24.1
mg/l
—
6
40
6
49
1.23
0.20
1.0
5.3
15.5
36.4
mg/l
—
6
41
20
227
0.87
0.19
3.9
3.0
—
—
—
0
0
12
100
1.21
0.18
2.1
2.2
—
—
—
0
0
9
78
1.16
0.15
1.1
2.1
10.2
9.8
g/l
—
9
70
9
78
1.16
0.15
1.1
2.1
2.9
3.2
g/l
—
9
65
9
82
1.10
0.15
1.9
1.9
—
—
—
0
0
42
392
1.08
0.15
2.6
2.1
—
—
—
0
0
17
150
1.14
0.15
1.9
1.5
—
—
—
0
0
9
83
1.09
0.15
1.1
2.0
6.9
7.6
g/l
—
9
68
9
83
1.09
0.15
1.1
2.0
—
—
—
0
0
9
83
1.09
0.15
1.1
2.0
3.8
3.8
g/l
—
9
65
5
44
1.14
0.10
1.2
1.2
—
—
—
0
0
10
92
1.09
0.03
1.9
2.1
1.1
1.1
%
—
10
92
11
112
0.98
0.00
1.9
1.7
—
—
—
0
0
14
139
1.01
0.00
1.9
1.5
—
—
—
0
0
12
115
1.05
0.00
1.6
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
6
68
0.88
0.00
1.8
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
362.4
—
0
5
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
6
61
0.98
0.00
1.3
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
9
94
0.96
0.00
1.9
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ALOPECANDRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ALOPECANDRO | 1.266 [1.01, 1.59] | 0.043 |
| Birth year | 0.997 [0.99, 1.01] | 0.532 |
During the follow-up period (1.1.1998 — 31.12.2019), 92 out of 1383 females with L12_ALOPECANDRO died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have L12_ALOPECANDRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.143% | No data |
| 5 | 0.796% | No data |
| 10 | 1.985% | No data |
| 15 | 3.694% | No data |
| 20 | 6.598% | No data |
Relationships between endpoints
↥Index endpoint: L12_ALOPECANDRO – Androgenic alopecia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data